Syngene Collaborates With Johns Hopkins University To Advance Early-Stage Drug Discovery

The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced a strategic collaboration with Johns Hopkins University, MD, U.S., to advance early‑stage drug discovery programs and platform technologies emerging from the university’s research labs.

The collaboration will be delivered by Syngene SynVent, a fully integrated drug discovery and development platform that spans discovery biology, medicinal and synthetic chemistry, DMPK (Drug Metabolism and Pharmacokinetics), toxicology, and early development. Syngene’s Connector model, which is designed to bridge high-potential, early-stage assets and technology platforms with strategic investors and downstream partnerships will be leveraged to bring together relevant stakeholders to sponsor research and secure licensing options for the resulting intellectual property.

Kenneth Barr, Senior Vice President, Head of Strategic Collaborations, Syngene International, said
“We are delighted to be working with a renowned institution like Johns Hopkins. We are uniquely positioned to translate pioneering research into credible therapeutic candidates, and our goal is to significantly compress the time required for high‑potential programs to become clinically relevant, creating a faster and more efficient pipeline of new medicines.”

According to Paul Nkansah, Senior Director of Corporate Partnerships at Johns Hopkins Technology Ventures, this novel collaboration model has the potential to link discoveries from Johns Hopkins laboratories with the drug discovery capabilities of Syngene, pharmaceutical and biotech partners, and investors – accelerating groundbreaking innovations developed at Johns Hopkins and turning promising science into credible development programs that could ultimately lead to new options for patients.

About SynVent
SynVent is Syngene’s proprietary integrated drug discovery platform that enables seamless progression from early target validation through translational interrogation, therapeutic discovery, and early development, across multiple therapeutic areas and modalities. It brings together multidisciplinary scientific teams and resources to support clients’ R&D portfolios, offering a one‑stop solution that enhances efficiency, accelerates timelines, and aligns with industry‑benchmark R&D milestones.

About Syngene
Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene’s team of over 8,200 employees including 5,600 scientists, brings both deep expertise and the capacity to deliver scientific excellence, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With over 2.5 mn sq. ft of specialized discovery, development, and manufacturing facilities across India and the U.S., Syngene works with 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis, and Merck KGaA. For more information, visit www.syngeneintl.com.